Human Growth Hormone
Research News and Information

Monday, November 23, 2009

Survey of long-term follow-up programs in the United States for survivors of childhood brain tumors.

13 Dec 2009 INTRODUCTION: Despite recognition that childhood brain tumor survivors often suffer multiple late effects following therapy, little is known regarding the long-term follow-up (LTFU) programs for these patients. METHODS: A 16-question survey was ... Read more...

Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.

30 Oct 2009 Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-associated growth hormone secreting ... Read more...

High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration.

29 Sep 2009 Insulin-like growth factor-I (IGF-I) is a known biomarker of recombinant human growth hormone (rhGH) abuse, and is also used clinically to confirm acromegaly. The protein leucine-rich alpha-2-glycoprotein (LRG) was recently identified as a putative ... Read more...

Latest indexed articles for 'Human Growth Hormone'

These are the very latest articles for this heading:

• Survey of long-term follow-up programs in the United States for survivors of childhood brain tumors. 13 Dec 2009
• Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. 30 Oct 2009
• Treatment with GH in adults with GH deficiency. Foreword. 4 Oct 2009
• X-linked isolated growth hormone deficiency: expanding the phenotypic spectrum of SOX3 polyalanine tract expansions. 29 Sep 2009
• High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. 29 Sep 2009
• [Treatment of pituitary adenomas] 25 Sep 2009
• Basal, pulsatile, entropic (patterned), and spiky (staccato-like) properties of ACTH secretion: impact of age, gender, and body mass index. 13 Sep 2009
• Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. 2 Sep 2009
• Fully traceable absolute protein quantification of somatropin that allows independent comparison of somatropin standards. Sep 2009
• Strategies for maximizing growth in puberty in children with short stature. 30 Aug 2009
• Growth hormone: the expansion of available products and indications. 30 Aug 2009
• Stimulant medication use and response to growth hormone therapy: an NCGS database analysis. 30 Aug 2009
• Diagnosis of growth hormone deficiency by using the arginine provocative test: is it possible to shorten testing time without altering validity? 30 Aug 2009
• The ABRF Edman Sequencing Research Group 2008 Study: investigation into homopolymeric amino acid N-terminal sequence tags and their effects on automated Edman degradation. 30 Aug 2009
• Immunogenicity of aggregates of recombinant human growth hormone in mouse models. 30 Aug 2009
• Recovery from neurological sequelae secondary to oncological brain surgery in an adult growth hormone-deficient patient after growth hormone treatment. 30 Aug 2009
• Partial restoration of GH responsiveness to ghrelin in Cushing's disease after 6 months of ketoconazole treatment: comparison with GHRP-6 and GHRH. 18 Aug 2009
• Is the response to growth hormone in short children born small for gestational age dependent on genetic or maternal factors? 16 Aug 2009
• Health-related quality of life of children and adolescents with growth hormone deficiency or idiopathic short stature - part 2: available results and future directions. 16 Aug 2009
• Assessment of health-related quality of life and patient satisfaction in children and adolescents with growth hormone deficiency or idiopathic short stature - part 1: a critical evaluation of available tools. 16 Aug 2009

See a longer list of these articles.

Technical information about 'Human Growth Hormone'

Definition: A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.

Chemical name: Somatotropin (human)

Registry Number: 12629-01-5

Descriptor UI: D019382

Alternative terms: Human Growth Hormone; Growth Hormone, Human; Somatotropin (Human); Somatropin (Human); hGH (Human Growth Hormone); Somatropin; Genotropin; Pharmacia Brand of Human Growth Hormone; Pharmacia Spain Brand of Human Growth Hormone; Genotonorm; Humatrope; Umatrope; Lilly Brand of Human Growth Hormone; Eli Lilly Brand of Human Growth Hormone; Irisfarma Brand of Human Growth Hormone; Maxomat; Sanofi Synthelabo Brand of Human Growth Hormone; Norditropin; Pisa Brand of Human Growth Hormone; Novo Nordisk Brand of Human Growth Hormone; Norditropin Simplexx; Norditropine; Zomacton; Ferring Brand of Human Growth Hormone; Omnitrope; Sandoz Brand of Human Growth Hormone; Recombinant Human Growth Hormone (Mammalian); r-hGH-M; r-hGH(m); Saizen; Allphar Brand of Human Growth Hormone; Serostim; Serono Brand of Human Growth Hormone; Cryo-Tropin; Cryo Tropin; CryoTropin; Cryopharma Brand of Human Growth Hormone; Nutropin; Hoffmann La-Roche Brand of Human Growth Hormone; Hoffmann La Roche Brand of Human Growth Hormone;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D06.472.699.631.525.425.875; D12.644.548.691.525.425.875;

History Note: 2003 (1997); for SEROSTIM use SOMATOTROPINS, RECOMBINANT (NM) 1996-2002; use NORDITROPIN (NM) 1992-1996

Technical Notes: GROWTH HORMONE, unspecified is also available; despite entry term, coordinate with RECOMBINANT PROTEINS for recombinant human growth hormone